← 홈

전체 프로그램

ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 201개
CGTBiologicstaleDonghua ZhangPreclinical

Recurrent/refractory multiple myeloma (Recurrent/refractory multiple myeloma, Recurrent/refractory multiple myeloma (r/r MM) patients received infusion of BCMA-GPRC5D CAR-T cells, r/r MM)

Multiple Myeloma · BCMA

#BCMA#CGT#Preclinical#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
AntibodyBiologicstaleSeagen Inc.Phase 2

anti-huCD40 mAb (SGN-40, SGN-40 (anti-huCD40 mAb))

Leukemia, Lymphocytic, Chronic · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#항체#면역항체+5
임상시험 1상태 ACTIVE
ADCBiologicstaleSeagen Inc.Phase 1

SGN-CD48A (SGN-CD48A)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 DISCONTINUED
CGTBiologicstaleWuerzburg University HospitalPhase 2

SLAMF7 CAR-T (SLAMF7 CAR-T)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#CGT#Phase2#세포유전치료#CAR-T+2
임상시험 1상태 ACTIVE
AntibodystaleOslo University HospitalPhase 3

daratumumab (Darzalex, Standard treatment of relapse with carfilzomib, dexamethasone, daratumumab)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleJanssenPhase 2

Teclistamab Monotherapy (Teclistamab Monotherapy)

Relapse Multiple Myeloma; Refractory Multiple Myeloma · FRα

#FR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleJanssenPhase 2

FDA-approved (Teclistamab, Teclistamab(FDA-approved))

Multiple Myeloma; Cytokine Release Syndrome · FRα

#FR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 DISCONTINUED
CGTBiologicstaleCellectis S.A.Phase 1

UCARTCS1A (UCARTCS1A)

Relapsed/Refractory Multiple Myeloma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 DISCONTINUED
CGTBiologicstaleDavid WaldPhase 1

UF-KURE-BCMA CAR T-cells (UF-KURE-BCMA CAR T-cells)

Multiple Myeloma; Multiple Myeloma in Relapse · BCMA

#BCMA#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 DISCONTINUED
ADCBiologicstaleGlaxoSmithKlinePhase 2

Unconjugated belantamab antibody (Unconjugated belantamab antibody)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
ADCBiologicstaleGlaxoSmithKlinePhase 2

belantamab mafodotin (Blenrep, GSK2857916, Unconjugated belantamab antibody and belantamab mafodotin)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 1상태 RECRUITING
CGTBiologicstalePaula C. & Rodger O. Riney Bloo…Phase 1

WS-CART-CS1 (WS-CART-CS1)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#CGT#Phase1#세포유전치료#CAR-T+2
임상시험 1상태 RECRUITING
CGTBiologicstalePeng LiuPhase 1

anti-CD19/BCMA CAR-T cells (anti-CD19/BCMA CAR-T cells)

Multiple Myeloma in Relapse; Multiple Myeloma Progression · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 ACTIVE
AntibodystaleJanssenPhase 3

KDD (carfilzomib/daratumumab/dexamethasone, carfilzomib/daratumumab/dexamethasone (KDD))

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleJanssenPhase 3

DVD (daratumumab/bortezomib/dexamethasone, daratumumab/bortezomib/dexamethasone (DVD))

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleJanssenPhase 3

DRD (daratumumab/lenalidomide/dexamethasone, daratumumab/lenalidomide/dexamethasone (DRD))

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleJanssenPhase 3

DPD (daratumumab/pomalidomide/dexamethasone, daratumumab/pomalidomide/dexamethasone (DPD))

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleUniversitätsklinikum Hamburg-Ep…Phase 3

ERD (elotuzumab/lenalidomide/dexamethasone, elotuzumab/lenalidomide/dexamethasone (ERD))

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodyBiologicstaleGilead SciencesPhase 2

the doxorubicin conjugate of milatuzumab (hLL1-DOX, hLL1-DOX (the doxorubicin conjugate of milatuzumab))

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleSpectrum Pharmaceuticals, IncPhase 2

indium-111-ibritumomab tiuxetan (indium-111-ibritumomab tiuxetan)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 DISCONTINUED

10 / 11 페이지

← 이전다음 →